Navigation Links
FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
Date:9/20/2007

king statements, including statements about the regulatory plans and timing for, and the expansion of, the Campath product label into earlier-line CLL, high-risk CLL, and combination and consolidation therapy. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others: the actual efficacy and safety of Campath in these indications; the actual timing and content of submissions to and decisions made by the U.S. Food and Drug Administration and other regulatory authorities, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our annual and interim reports to the Frankfurt Stock Exchange and in our reports filed with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to
'/>"/>

SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. UW Board of Regents approves $134 million medical research facility
7. FDA approves Bone Cares Hectorol for treatment of kidney disease
8. New Microarray Labeling Kit for Preparing cDNA Probes
9. Antibodies for Studying NMDA Receptor Protein Expression and Synapse-Specific Immunolabeling
10. aRNA Synthesis and Labeling for Array Analysis
11. Amino Allyl Labeling for Array Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 Vala ... the U.S. Environmental Protection Agency (EPA). This new ... developmental toxicity models, including tests designed to assess ... and the formation of connections between neurons (synapses), ... neurodifferentiation and synapse formation by environmental pollutants likely ...
(Date:7/30/2014)... 30, 2014 LayerBio, Inc., an MIT ... its first round of seed financing from friends and ... efforts to develop a novel sustained-release product for ophthalmology. ... investors and their commitment to this important work," said ... is one of many areas in which innovations in ...
(Date:7/29/2014)... have hurdled a number of significant technological challenges ... observing technology originally created for the James Webb ... Investigator Harvey Moseley, a scientist at NASA,s Goddard ... that electrostatically actuated microshutter arrays that is, ... are as functional as the current technology,s magnetically ...
(Date:7/29/2014)... Calif. , July 29, 2014 Human ... and therapeutic company focused on extending the healthy, high ... Franz Och , Ph.D., an expert in machine ... Scientist. Och comes to HLI from Google where he ... Translate. He will report directly to HLI Co-Founder and ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3
... TORONTO, May 5 /PRNewswire-FirstCall/ - Lorus Therapeutics ... company dedicated in,the research, development and commercialization ... of cancer, announced today that it has,strengthened ... of Dr. Saeid,Babaei to Vice-President of Business ...
... 8, 2008, at,8:30 a.m. Eastern/2:30 p.m. Central European/5:30 ... CTIC ; MTA) management team will,host a ... first,quarter achievements and financial results., Conference ... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time ...
... - YM BioSciences Inc.,(AMEX: YMI , TSX: ... and commercializes differentiated products for patients worldwide,today announced ... product AeroLEF(TM) will be presented at The 27th ... takes place May,8-10, 2008 in Tampa, Florida., ...
Cached Biology Technology:Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 2Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 3Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 4YM BIOSCIENCES ANNOUNCES PRESENTATIONS FOR AEROLEF(TM) AT AMERICAN PAIN SOCIETY ANNUAL MEETING 2
(Date:7/30/2014)... Scientists are searching through a massive collection of ... 50 years ago, and the effort is yielding fresh ... inhabited. , When the collection is fully curated, a ... the largest unbiased Dominican amber collection in the world, ... discovery thus far is that of a pygmy locust, ...
(Date:7/30/2014)... Steven Chown has been awarded the Scientific Committee ... in Antarctic Research. , SCAR, an inter-disciplinary international ... international scientific research in the Antarctic region, and ... the Earth system. The organisation also provides scientific ... responsible for governing the region. , The medal ...
(Date:7/30/2014)... spinal cord injury (SCI), traumatic brain injury (TBI) and ... has been learned over the past 30 years regarding ... regulate axon growth, but this large body of information ... Lemmon and his team from University of Miami in ... but a consensus is emerging that one contributing factor ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2
... telescopes to restore vision, and smart nappies to detect ... technologies that promise to transform medicine, according to this ... are made by Professor Donald Combs of the Eastern ... that are in varying stages of development and on ...
... Despite the fact that the people of India ... population, they have been underrepresented in studies related ... modernization, complex genetic diseases associated with urban and ... genetic cataloging and association studies of particular importance. ...
... first-ever computed tomography (CT) evaluation of King Tutankhamun’s mummy ... ancient pharaoh died. The CT images and results of ... of the Radiological Society of North America (RSNA). , ... Cairo University in Egypt, was part of an international ...
Cached Biology News:Five new technologies that promise to transform medicine 2Researchers make progress in studying genetic traits of India-born populations 2Radiologists attempt to solve mystery of Tut's demise 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Clone/PAD: ZMD.330. Immunogen: Synthetic peptide derived ... rat and mouse protein kinase C zeta ... rat and mouse PKCzeta protein. Recognizes ... not cross-react with PKCiota/lambda. Reactivity: Mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: